Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

67.62 +0.42 (+0.63%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
59 60 Next >
Guardant Health (GH) Stock Sinks on Disappointing Blood Test Results
Guardant spent more money than it took in while hoping to become a leader in cancer diagnosis, but accuracy remains a problem. 
Via InvestorPlace
2 Best Biotech Stocks to Buy Right Now
Demand for medicines and vaccines has nowhere to go but up over the long run. 
Via The Motley Fool
FDA Extends Review Period For AstraZeneca-Merck Partnered Cancer Drug, Lynparza
Via Benzinga
AstraZeneca Awards $4M to Nonprofit Organizations to Advance Health Equity
From AstraZeneca
Via Business Wire
Mirati Wins FDA Approval For Amgen-Rivaling Cancer Drug As Wild Stock Swing Continues
FDA action on its KRAS-blocking drug could help recently downtrodden Mirati. 
Via Investor's Business Daily
Why Shares of Compugen Rose 16.5% on Wednesday
Market factors and a company announcement helped the stock climb. 
Via The Motley Fool
2 Top Healthcare Stocks to Buy for the Long Haul
These two companies are just getting started. 
Via The Motley Fool
AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
Via Benzinga
AstraZeneca Highlights Detailed Data From Two Breast Cancer Trials
Via Benzinga
Camizestrant Significantly Delayed Disease Progression in Advanced ER-Positive Breast Cancer, Adding at Least 3.5 Months Benefit Versus FASLODEX® (fulvestrant)
From AstraZeneca
Via Business Wire
Capivasertib Plus FASLODEX® (fulvestrant) Reduced the Risk of Disease Progression or Death by 40% Versus FASLODEX in Advanced HR-Positive Breast Cancer
From AstraZeneca
Via Business Wire
AstraZeneca's Enhertu Cuts Risk Of Death By 36% VsTrastuzumab In Metastatic Breast Cancer
Via Benzinga
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Breast cancer in DESTINY-Breast03
From AstraZeneca
Via Business Wire
US Supports Delay On COVID Patent Waiver Extension Decision
Developing countries have been pushing for a patent waiver extension for COVID-19, which many developed countries argue could discourage pharma companies from responding rapidly to future global health... 
Via Benzinga
Is Amgen Stock a Buy for Income Investors?
Amgen's dividend yield is materially higher than the S&P 500 index's yield. 
Via The Motley Fool
Optimism Building for Advancing Pancreatic Cancer Treatment Therapies
EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:RCUS),(NASDAQ:AZN),(NYSE:BMY),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
2 Stocks That Could Surprise Investors in 2023
Investing in safe healthcare stocks may be an underrated strategy to deploy. 
Via The Motley Fool
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Cosmos Holdings stock is up 618% in November likely due to a short squeeze. This article explains why Cosmos Holdings may still be a good long-term investment 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
AstraZeneca Showcases Strength of Hematology Portfolio and Pipeline Across Multiple Hard-to-Treat Conditions at ASH 2022
From AstraZeneca
Via Business Wire
Analyst Says Coinbase 'A Waste Of Time', Taylor Swift's Concert Fiasco Under DOJ Probe, Shopify Clocks Record Black Friday Sales: Top Stories Monday, Nov. 28
CNBC 
Via Benzinga
AstraZeneca Bets On UK Listed Firm For Lung Diseases
Via Benzinga
C4X Discovery Holdings plc: C4XD signs exclusive global licence worth up to $402 million¹ with AstraZeneca for the development and commercialisation of NRF2 Activator programme
From C4X Discovery Holdings plc
Via GlobeNewswire
European Official Says COVID-19 Booster Uptake Disappointing In The Region
Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather... 
Via Benzinga
Mirati Therapeutics Surges As Big Pharma Reportedly Preps For A Buyout Battle
There are reportedly numerous companies in the mix and they're all awaiting data next month. 
Via Investor's Business Daily
AstraZeneca Aims to Redefine Breast Cancer Care With New Data Across the Treatment Spectrum At SABCS 2022
From AstraZeneca
Via Business Wire
2 Breakout Growth Stocks to Buy for the Long Haul
These two Russell 1000 members know how to grow revenue. 
Via The Motley Fool
2 Stocks to Buy Whether or Not a Recession Is Coming
Both have outperformed the stock market this year. 
Via The Motley Fool
Why Shares of Compugen Jumped 17.86% on Thursday
The company is receiving a $7.5 milestone payment from AstraZeneca for the use of one of its therapies. 
Via The Motley Fool
How Long Can This Top Stock Continue Defying the Bear Market?
It could only be the beginning for this pharma giant. 
Via The Motley Fool
Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics
From Alexion, AstraZeneca Rare Disease
Via Business Wire
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS